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The rising number and increasing longevity of the elderly population calls for improve-
ments and potentially a more personalized approach to the treatment of cancer in this 
group. Elderly patients frequently present with a number of comorbidities, complicating 
surgery and chemotherapy tolerability. In the case of ovarian cancer, elderly women 
present with more advanced disease, making the issue of providing adequate treatment 
without significant morbidity critical. Most studies support the application of standard 
of care treatment to elderly women with ovarian cancer, yet it seems to be offered less 
frequently in the elderly. The objective of this review is to examine the application and 
outcome of standard of care treatment in elderly women with ovarian cancer. The aim is 
to ultimately improve the approach to treatment in this group.
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iNTRODUCTiON
The elderly population, defined as 65 years and older, is expected to reach 80 million in the United 
States over the next two decades (1). Ovarian cancer is common among older women, with estimates 
suggesting that half of the women living with ovarian cancer are over 65 years old (2, 3). Over two-
thirds of new cases are in women over 55 years old, with the median age at diagnosis being 63 (4). 
While some cancers, such as breast, generally become more indolent with increasing age, the reverse 
is seen in ovarian cancer (5), resulting in increasing complexity of treatment. Many studies continue 
to investigate why survival in the elderly differs so much from that of younger cancer patients. Freyer 
and colleagues in a 2013 review proposed various theories to explain these higher death rates. They 
proposed that this could be due to more aggressive cancer with advanced age, inherent resistance to 
chemotherapy, multiple concurrent medical problems, and physician and healthcare biases toward 
the elderly that lead to inadequate surgery, less than optimal chemotherapy, and poor enrollment in 
clinical trials (6).
Both treatment administered and outcomes observed in the elderly ovarian cancer popula-
tion have differed from their younger counterparts. For example, a Surveillance, Epidemiology 
and End Results (SEER) data analysis of almost 10,000 elderly women (>65 years) between 1991 
FiGURe 1 | Relative survival rates by age in ovarian cancer patients 
over 20-year study period (8).
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and 2007 found that over the past couple of decades, primary 
surgery had significantly decreased from 63.2 to 49.5%, while 
primary chemotherapy doubled from 19.7 to 31.8% (7), as 
later described in Figure  3. In addition, a German study 
found that ovarian cancer patients aged 15–54 had a strong 
continuous trend of improving survival, as did patients aged 
55–74, yet elderly patients >75  years saw no improvement 
in survival during the 1979–2003 study period. As the age 
gradient substantially widened over time, reaching a relative 
survival difference of 50% between the two groups, it was the 
strongest age gradient observed among 15 examined cancers 
after a 20-year analysis Figure 1 (8). Both of these examples 
illustrate how treatment and outcomes continue to differ from 
women in younger age groups. Acknowledging these differ-
ences as well as the deficits in the literature is the objective 
of this review. Once these deficits are better defined, research 
can be initiated.
MeTHODS
A PubMed literature review was conducted using various combi-
nations of the following search terms: “ovarian cancer,” “elderly,” 
“gynecologic(al) cancer(s),” “treatment,” and “care.” The articles 
were screened for original articles and reviews published between 
2005 and 2015. Only English articles were reviewed. Seventy-six 
articles met these inclusion criteria.
Baseline variables Predictive of Outcome
Several studies have examined the diagnosis of ovarian cancer 
in elderly patients. Ovarian cancer is a disease of the elderly as 
the average age of diagnosis is 63. For example, in a large study 
by Poynter et al., older age at baseline was the only significantly 
associated risk factor for developing ovarian cancer in elderly 
women (9). Although ovarian cancer is typically diagnosed at 
an advanced stage, an even larger proportion (80%) of elderly 
women present with Stages III–IV disease (6). Analysis of SEER 
data from 1988 to 2001 found that in over 28,000 women, younger 
women were two to three times more likely to be diagnosed with 
early-stage (I–II) disease than their elderly counterparts (10). 
Other studies have shown similar results (11). A separate SEER 
analysis of 4,000 advanced ovarian cancer patients diagnosed 
between 1992 and 1999 illustrates the consequence of elderly 
women being diagnosed with higher stages of disease, as sur-
vival is significantly associated with stage (12). These SEER data 
are also described in Figure  3. When comparing the elderly 
(65–74 years) with the very elderly (≥75 years), increased age 
was also associated with advanced stage and higher grade (13). 
While other studies may not support this trend (10, 11, 14–18), 
the majority suggest the importance of age as a baseline that 
affects treatment outcomes.
Comorbidities are common in all elderly women, regardless 
of cancer status, but women with ovarian cancer in general 
had a much higher incidence of comorbidities than cancer-free 
women. Because of this, understanding the role of comorbid 
conditions in elderly ovarian cancer treatment and outcomes will 
be crucial for optimal personalized treatment in this group (19). 
The complexity of ovarian cancer treatment, including surgery 
and chemotherapy, may limit the ability of elderly women with 
comorbidities to tolerate radical surgery and toxic therapeutic 
regimens.
Because of this, having a prognostic tool to predict the impact 
of covariates on overall survival (OS) would be of value in this 
complex patient population. The GINECO study used three 
separate phase II trials to develop a new prognostic tool, called 
the geriatric vulnerability score (GVS), which can be utilized to 
predict survival in elderly (≥70 years) patients with advanced 
ovarian cancer. The best-fitting model delivered a survival score 
equal to exp(0.327 × GVS), where the GVS is the sum of the 
following of a scale of 0–5 (each with a value of one): albumin 
<35 g/l; activities of daily living (ADL) score <6; instrumental 
activities of daily living (IADL) score <25; lymphopenia <1 G/l; 
and Hospital Anxiety and Depression Scale (HADS) >14. The 
GVS was significantly differentiated between two groups: those 
with a score <3 having an 82.1% chemotherapy completion 
rate, while those over 3 only observed 65.5% completion rates. 
Women with a GVS ≥3 were over twice as likely to have grade 
≥3 non-hematological toxicities, twice as likely to have seri-
ous adverse event, and experienced more unplanned hospital 
admissions (20).
Primary Surgical Treatment
Initial therapy for ovarian cancer following diagnosis includes 
a combination of surgery and chemotherapy. Patients with the 
best prognosis include those who undergo surgical cytoreduc-
tion to no gross disease and receive platinum and taxane-based 
chemotherapy, with some receiving treatment through an intra-
peritoneal infusion.
Many recent studies have examined how primary treatment 
in the elderly compares to younger women with ovarian cancer 
(Figure 2). For example, in an analysis of over 10,000 patients 
with ovarian cancer, the elderly were less likely to receive compre-
hensive surgical care, as defined by International Classification 
of Disease, 9th Revision (ICD-9) diagnosis and procedure 
FiGURe 3 | Summary of Selected Surveillance, epidemiology and end Results (SeeR) data (7, 10, 12, 54, 55).
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FiGURe 2 | Primary surgical treatment for elderly women with ovarian cancer.
3
Gibson et al. Ovarian Cancer Treatment in Elderly
Frontiers in Oncology | www.frontiersin.org March 2016 | Volume 6 | Article 63
codes (21). Similarly, an analysis of over 23,000 advanced ovarian 
cancer patients in the Netherlands found that about one-third of 
elderly patients received no therapy (22). Other studies support 
the trend in elderly women receiving suboptimal treatment (11, 
13, 15, 18, 22–27). A 961-patient study even found elderly age 
to be independently predictive of not receiving cytoreductive 
surgery and standard combination chemotherapy (24). A SEER 
analysis of 28,165 women with ovarian cancer found that younger 
women were significantly more likely to undergo primary surgi-
cal procedures than the elderly (10) (Figure  3). This was sup-
ported by other studies as well (23). Although some studies did 
not confirm this difference in treatment based on age (16, 17, 28, 
29), the bulk of the data demonstrates a disproportionate number 
of elderly women receiving suboptimal treatment.
Interestingly, most studies do indicate that optimal treatment 
in the elderly is feasible and acceptable, with similar outcomes 
observed between age groups (15, 16, 23, 24, 27, 30–32). After 
adjusting for age and stage of ovarian cancer, optimal treatment 
had a significant impact on survival, suggesting that focus should 
be placed on optimal treatment for patients of all ages with ovar-
ian cancer (32). When comparing the elderly and very elderly, 
multiple studies found no significant difference in perioperative 
complications, with progression-free survival (PFS) and OS being 
similar (16, 29, 33).
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While surgery may be feasible, the residual disease volume 
post-debulking surgery has been found to be higher for elderly 
patients, which significantly impacts PFS and OS (11, 16, 27, 29, 
34–36). A Mayo Clinic study of women with advanced ovar-
ian cancer found that residual disease had a larger and more 
significant impact in the very elderly, with a fourfold decrease 
in median survival when compared to younger patients (37). 
With perhaps a higher rate of residual disease left at the time 
of surgery and a greater impact on outcomes, such as survival, 
some question the use of this aggressive treatment in this 
population.(23, 38), However, elderly women who do undergo 
primary debulking surgery have better disease-free survival 
and OS than those who had interval debulking (33). Yet, the 
elderly have also been found to have a statistically higher rate 
of large bowel resection than their younger counterparts (15). 
Hospitalization data are conflicting, with some studies showing 
days of hospitalization or ICU stay to be longer in the elderly 
(28, 33), while others contradict this (23). Discrepancies are 
likely influenced by selection bias. Further investigation with 
larger sample sizes is warranted.
In a Maryland state-wide study, it was observed that university-
type hospitals were significantly less likely to have admitted the 
elderly patients when compared to younger patients, with the 
majority of elderly admissions being for surgeries under emer-
gency conditions. Interestingly, older women with ovarian cancer 
were also significantly more likely to have a different operating 
surgeon than the attending physician of record. The elderly also 
had a higher adjusted cost of hospital-related care with more bill-
able procedures, and a 30-day mortality rate 2.3 times higher than 
that of younger patients. When analyzing surgeon-type, elderly 
patients of high-volume surgeons (≥10 cases/year) billed twice 
as manyprocedures, had nearly a tripled cost of hospital care, and 
twice as many comorbidities as younger patients. Interestingly, 
62% of elderly women saw high-volume surgeons even though 
these surgeons only represented 3.4% of the surgeons in the study. 
Similarly, while only 18.4% of hospitals in the study were consid-
ered high-volume (≥20 cases/year), the majority (60%) of elderly 
women were treated at these hospitals and had more procedures 
billed and more comorbidities (28).
Earle et  al. examined the impact of surgeon specialty on 
outcome for 3,067 elderly ovarian cancer patients and found that 
those treated by gynecologic oncologists had superior outcomes 
to those treated by general gynecologists or general surgeons. 
Advanced-stage disease patients were more likely to undergo 
debulking if the surgery was performed by a gynecologic oncolo-
gist as opposed to a general gynecologist or general surgeon. 
Survival among patients operated on by gynecologic oncologists 
or general gynecologists was far better than that among patients 
operated on by general surgeons (39). This is supported by another 
study, which found surgeries performed by non-gynecologic 
oncologists observed the risk for mortality to double (31).
A study of 2,087 women with ovarian cancer from the American 
College of Surgeons National Surgical Quality Improvement 
Program (ACS-NSQIP) database found there to be a high risk of 
perioperative mortality and morbidity within 30 days in elderly 
patients with ovarian cancer (40), as supported by other data 
outcomes on high risk women (12, 38). The elderly were also 
more likely to develop pulmonary and septic complications, and 
were nine times more likely to die and 70% more likely to develop 
complications within 30 days of surgery (40). Similarly, Moore 
et al. demonstrated elderly patients may not tolerate surgery and 
combination chemotherapy, paying a high price in post-operative 
complications and death (41).
Different types of procedures have been examined in the 
elderly as well. One study examined the effects of interval debulk-
ing after neoadjuvant chemotherapy and hyperthermic intra-
peritoneal chemotherapy (HIPEC) in the elderly with advanced 
ovarian cancer as an alternative to initial complex surgery. This 
study found that the elderly group did not receive benefit from 
the interval cytoreduction with HIPEC treatment and instead 
experienced postoperative morbidity, with the most common 
being grade 4 hemoperitoneum and grade 3 intra-abdominal 
fluid collection in 22.2% of women (17). Another study that 
evaluated the feasibility and safety of extensive upper abdominal 
surgery (EUAS) in elderly patients with advanced ovarian cancer 
found no significant difference to that of younger patients, and 
concluded that EUAS procedures are feasible in this elderly 
population (35).
The impact of nutritional status on survival outcomes 
was examined by Alphs et  al., who found that poor nutrition 
was associated with poor survival outcomes. Albumin levels 
≥3.7 g/dl were associated with a 40% reduction in risk of mor-
tality in the elderly population and, overall, elderly women had 
a 2.6-fold greater risk of mortality when compared with younger 
women (31).
Most conflicting, however, was univariate and multivariate 
analysis on the impact of age on treatment outcomes. Multiple 
studies showed increased age was independently associated with 
a significant, negative impact on survival (10, 12, 18, 22, 25, 31, 
34, 40, 42, 43), while others show no significant, age-related 
impact on survival (15, 16, 23, 24, 26, 27, 30–32). Some of these 
studies include disease-free survival outcomes, which may help 
explain the conflicting data. The Centers for Disease Control and 
Prevention (CDC)-funded cancer registries examined the impact 
of age on survival in 2,367 women with ovarian cancer. Survival 
rates were lower in the oldest groups, especially in those with 
advanced disease. For example, 3-year survival in patients with 
stage IV was only 13% in the elderly compared to 50% in women 
under 35 years old. The adjusted risk of death doubled from 40% 
in younger women to 80% in the elderly. The CDC confirmed 
the independent adverse effect of age on survival in this patient 
population (25).
Significant survival advantages were seen in the younger 
patients with early-stage disease, as young age was an independent 
prognostic factor for increased survival. Advanced-stage disease 
had poorer survival in the elderly (10). As defined above, optimal 
treatment includes cytoreductive surgery with combination 
chemotherapy, and a 1992–1999 SEER analysis of almost 4,000 
advanced ovarian cancer patients supports this treatment with the 
observation that elderly patients who received both surgery and 
chemotherapy showed significantly improved survival compared 
to either treatment alone (12) (Figure 3). However, it is worth 
noting that these findings may be influenced by selection bias. A 
retrospective analysis also evaluated each treatment individually 
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and found that primary surgery was more beneficial than primary 
chemotherapy on survival outcomes (30, 44).
While NACT in elderly women only demonstrated a trend to 
improved PFS and no improvement in OS, NACT benefits were 
clearly demonstrated in a 62-patient study. Nearly a threefold 
increase in the rate of cytoreduction to no macroscopic disease 
was seen in women who received NACT when compared to those 
without. The NACT patients also had significantly less blood loss 
during surgery and required fewer small bowel resections (45).
In a study of almost 600 women with ovarian cancer, elderly 
women had a much poorer prognosis, possibly related to the sig-
nificantly higher incidence of suboptimal treatment in this group. 
While no significant difference in PFS was observed between the 
two groups, median OS was over twice as long in the younger 
population (18). With no difference in PFS observed, the differ-
ence in OS may instead be attributed to comorbidities preventing 
second- or third-line chemotherapy treatment as opposed to 
strictly the result of suboptimal treatment.
An analysis of the OVCAD consortium, including 275 patients 
with ovarian cancer, found that the postoperative 60-day mor-
tality rate was 5.25-fold higher in the elderly than in younger 
patients. The elderly also had a significantly worse median PFS 
and OS. Interestingly, age itself was not a prognostic factor for 
PFS in multivariate analysis, reiterating the significant role of 
optimal treatment on survival outcomes in the elderly (26). These 
results also demonstrate the confounding impact of age, grade, 
and stage on PFS outcomes.
Adjuvant Chemotherapy
The indications for using of standard adjuvant chemotherapy 
in the elderly are inconsistent. As noted above, whether age is 
an independent prognostic factor for survival is unclear. Some 
studies show increasing age to be significantly associated with 
poorer survival outcomes (37, 43, 46–48), while others demon-
strate no significant differences in survival outcome among the 
elderly (11, 16, 49–51). Not receiving adjuvant chemotherapy was 
found to negatively impact OS (34), and having more than three 
chemotherapy cycles was found to be an independent prognostic 
factor for OS in the elderly (18). When comparing the elderly 
(70–75 years old) to the very elderly (>75 years old), there was 
no difference in toxicity, dose reduction, and treatment delay or 
discontinuation (16). Even given these data, suboptimal chemo-
therapy administration in the elderly continues to be observed in 
most studies (13, 24, 27, 50–53). However, the impact of selection 
bias on these data cannot be underestimated.
While it is apparent the elderly do not receive equivalent 
standard of care chemotherapy treatment as their younger 
peers, some studies suggest that the elderly do not tolerate this 
regimen (41, 43). In one study of 109 patients, elderly women 
were less likely to complete all planned cycles of intraperitoneal 
chemotherapy when compared to a younger cohort. In addi-
tion, more intravenous chemotherapy was completed by elderly 
women who were optimally debulked as compared to those 
with residual disease (49). Another study found that the very 
elderly were prescribed combination chemotherapy much less 
frequently than younger patients, had significant differences in 
delayed initiation of chemotherapy, and six-cycle completion 
rate was only half that of the younger group (47, 52). The very 
elderly also had a 30-day mortality rate fourfold that of their 
elderly counterparts (46).
Common chemotherapy toxicities in the elderly across multi-
ple studies included: grade 3–4 hematologic and gastrointestinal 
toxicities (16) and grade 3–4 neutropenia (51), with the use of 
paclitaxel as an independent prognostic factor for worse survival 
and increasing toxicities (48). While these trends in toxicity 
among the elderly are worth noting, the small study sizes may 
be misleading, as many studies show no significant difference in 
toxicities between age groups (11, 14, 50, 52).
A SEER analysis from 1991 to 2002 found that non-platinum 
chemotherapeutic regimens (administered in 18% of women) 
had higher rates of hospitalizations for gastrointestinal and hema-
tologic conditions or infections compared to platinum-based or 
platinum–taxane combination regimens in 9,361 elderly women 
with ovarian cancer. While age was a significant predictor for hos-
pitalization due to infection and cardiovascular diseases, older 
age did not predict gastrointestinal and hematologic toxicities 
(54). A separate, larger SEER analysis among over 9,000 women 
with ovarian cancer during the same 1991–2002 period found 
taxane therapy to double, and platinum–taxane therapy to triple, 
the risk of peripheral neuropathy when compared to elderly 
not receiving chemotherapy treatment. Risk was greater with 
an increasing number of cycles. Monitoring of peripheral neu-
ropathy in this patient population receiving these chemotherapy 
regimens is warranted (55). The results of both SEER analyses are 
summarized in Figure 3.
A National Cancer Institute Common Toxicity Criteria (NCI 
CTC) analysis found that younger women received standard-
dose chemotherapy nearly three times as often as the elderly 
(52). One study examined dose-delay in chemotherapy among 
elderly ovarian cancer patients and found that it was associated 
with a decrease in OS, even after controlling for age, stage, 
residual disease, and number of chemotherapy cycles received. 
This is of significance, as elderly patients frequently require 
chemotherapy dose reductions and delays in administration, 
and multivariate analysis suggested that dose-delays are an inde-
pendent factor associated with decreased OS (56). However, a 
retrospective, multi-center analysis demonstrated no difference 
in survival outcomes between the reduced-dose and standard-
dose elderly patients, and with the elderly more commonly on 
reduced-dose regimens, the authors suggested that carboplatin/
paclitaxel may be better tolerated and equally as effective in this 
elderly population (51).
The 779-patient AGO OVAR-3 phase III study evaluated 
first-line platinum/paclitaxel in ovarian cancer patients, and 
found that ECOG performance status 2, measurable disease, and 
early discontinuation of therapy were much more common in 
the elderly (14). Another analysis of the same study found that 
young patients achieved no residual tumor after surgery more 
often and had significantly better survival when compared to 
the elderly, even when comparing those that were completely 
debulked across ages (43).
In a study of over 450 women with ovarian cancer, elderly 
women were more likely to receive carboplatin mono-
therapy, while younger patients were more likely to receive 
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paclitaxel-containing chemotherapy. Only about half of the 
elderly patients received 100% paclitaxel relative dose intensity 
(RDI), while over two-thirds of the younger patients did. While 
the median OS of younger patients was significantly longer than 
that of older patients, PFS did not differ significantly between 
the two age groups (11). A similar study examined platinum–
taxane chemotherapy outcomes in the elderly, and with only 
half of elderly women getting platinum-based chemotherapy, 
an examination of treatment outcomes is warranted. The study 
found that age was not independently associated with outcomes 
in this 292-patient study of women with advanced ovarian 
cancer (50).
Finally, when examining treatment by physician type, elderly 
women seen by gynecologic oncologists were significantly more 
likely to receive adjuvant chemotherapy than those seen by gen-
eral gynecologists and general surgeons (39).
Recurrent Ovarian Cancer
In patients with advanced disease, nearly 85% will relapse even 
after adequate initial treatment (57). In these cases, treatment 
usually involves follow-up chemotherapy, avoiding surgery and 
surgery-related morbidities. To address this problem, a small 
study examined cytoreductive surgery and HIPEC in elderly 
women (57). No patients died immediately after surgery or 
from HIPEC-related complications. Median hospital stay was 
13 days, with 20% of patients presenting G3–G4 complications. 
Median OS was 35 months, with median disease-free survival of 
15.6  months. When the extent of carcinomatosis was assessed 
using the peritoneal cancer index (PCI), there were significant 
differences observed. For example, all patients with PCI >13 
relapsed during the 2-year follow-up, and the authors concluded 
that in patients with PCI < 13, maximal cytoreductive surgery 
associated with HIPEC may improve the disease-free survival 
of elderly, recurrent ovarian cancer (57). Further studies with 
HIPEC are necessary, as it is a controversial treatment option 
with conflicting data.
The CALYPSO sub-study compared carboplatin–pegylated 
liposomal doxorubicin (C–PLD) with carboplatin–paclitaxel 
(C–P) in patients with late-relapsing recurrent ovarian cancer 
in elderly versus younger patients. While the elderly women had 
significantly fewer ≥Grade 2 allergic reactions, they had more 
≥Grade 2 sensory neuropathy. Myelosuppression and comple-
tion rates of treatment did not differ between groups. Within 
the elderly patients, C–P was associated with more ≥Grade 2 
alopecia, sensory neuropathy, arthralgia/myalgia, and severe 
leukopenia plus febrile neutropenia, while C–PLD was associ-
ated with more ≥Grade 2 hand–foot syndrome, providing 
a better therapeutic index with less toxicity in this elderly 
population (58).
The SOCRATES study assessed the pattern of care in patients 
with recurrent platinum-sensitive ovarian cancer at 37 Italian 
sites. Among the 493 patients analyzed, the recurrence-free inter-
val (RFI), PS, and number of disease sites were similar between 
the elderly and younger women, but fewer elderly patients 
underwent secondary cytoreduction. The mean number of 
chemotherapy lines received for recurrence was similar, with the 
elderly patients more frequently receiving single-agent platinum 
at second line. The response rate to second-line chemotherapy was 
higher in younger patients, demonstrating a significant increase 
in median OS from recurrence. At multivariate analysis, age at 
recurrence was independently associated with survival, and the 
authors conclude that age is an unfavorable factor independently 
associated with a worse prognosis (59).
Quality of Life
Quality of life (QoL) data available for review are extremely lim-
ited. The phase III AGO OVAR-3 trial evaluated QoL in elderly 
ovarian cancer patients using the European Organization for 
Research and Treatment of Cancer (EORTC) QoL questionnaire, 
and found no significant differences between the elderly and 
younger subgroups (14).
Also relating to QoL, in an analysis of over 8,000 elderly 
women with ovarian cancer, nearly 20% of women developed 
bowel obstruction after cancer diagnosis, of which all non-
adhesion-related obstructions were considered pre-terminal 
events regardless of treatment type. Because of this, the authors 
suggest that patient comfort, not survival, should be the primary 
focus in this patient group (60).
CONCLUSiON
The data available for analysis regarding treatment outcomes in 
elderly ovarian cancer patients are conflicting; however, some 
general trends can be noted. As elderly women present more 
often with advanced stage (III–IV) disease, having prognostic 
tools to optimize treatment will be crucial in future care in this 
population. Most studies focused on the primary treatment for 
elderly women with ovarian cancer, with many suggesting that 
the aim should be focused on delivering optimal treatment, 
regardless of age. When providing suboptimal treatment to 
the elderly because of their age, numerous studies demonstrate 
suboptimal results with significantly lower survival outcomes. It 
would be important to develop tools to determine which elderly 
patients can actually tolerate aggressive therapy. While there is 
no consensus on whether age alone is an independent prognostic 
factor in this patient population, there seems to be consistency 
that optimal treatment (cytoreductive surgery with no residual 
disease remaining and combination chemotherapy) warrants 
further investigation in this population. To improve consistency 
among data, future studies should aim to determine an appropri-
ate age defining “elderly.”
With a growing elderly population expected to double over 
the next couple of decades, further investigation into how to best 
treat this population is essential in optimizing future healthcare 
delivery to elderly women with ovarian cancer.
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